Press Releases

NecstGen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic’s 2G UNic™ premium vector technology. Both companies, located on the Leiden Bio Science Park, recognise the need to increase viral titres and optimise production process

The Aesthetic and Anti-Ageing Medicine World Congress India 2023, the inaugural Indian edition of the globally renowned AMWC event series, made its remarkable debut at Hotel Sahara Star, Mumbai. This annual groundbreaking event, organised by Informa Markets in India, is poised to reshape India's Aesthetic Medicine Industry in the coming years.  Fostering knowledge exchange, networking, innovation adoption, and industry growth while ensuring safe and high-quality patient care, AMWC In

Almirall S.A. (BME: ALM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy. The positive CHMP opinion is now being reviewed by the Eur

Cure Genetics and Frametact Limited, a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a collaborative development and licensing agreement. The partnership will leverage Cure Genetics' proprietary VELP™ platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of familial neurological diseases. According to the agreement, Cure Genetics will receive an upfront and milestone payment

Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine (“5-MeO-DMT”) organic synthesis scheme. This significant achievement marks a major breakthrough in

Bioiberica, a global life science company committed to improving the health and well-being of people, animals and plants, is set to participate in CPHI 2023, where it will showcase its investment in scientific research, sustainable development and strategic partnerships for a more resilient future. Alongside its market-leading API portfolio, the company will present the latest research for its mobility, digestive and skin health branded ingredients. Attendees will also have the opportunity to

NEC Corporation has been selected to participate in a vaccine/new modality research and development project beginning in FY2023. NEC was selected following its submission of a research project titled "Development of universal vaccine design technology using computational science" in response to a public call for proposals by the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA), which operates under the Japan Agency for M

Mainz Biomed N.V.a molecular genetics diagnostic company specializing in the early detection of cancer, announced today positive topline results from its ColoFuture study. The ColoFuture study is a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert®, the Company’s highly efficacious, and easy-to-use screening test for colorectal cancer (CRC) which is being commercialized across Europe a

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that it has received the cGMP Manufacturing Compliance Certificate, following the successful inspection by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) at its UK site. The ATMP business was announced in early 2021 and the facility is located in the Cell and Gene Therapy Catapul

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has submitted a request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM). HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and already has Orph